AIM IMMUNOTECH INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
AIM IMMUNOTECH INC. (AIM) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $88.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-07
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $88.00K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $58.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $117.00K.
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $176.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $88.00K 10-Q · filed 2026-08-07 |
| 2025-09-30 | $58.00K 10-Q · filed 2025-11-17 |
| 2025-06-30 | $117.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $176.00K 10-Q · filed 2025-05-15 |
| 2024-09-30 | $72.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $136.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $186.00K 10-Q · filed 2024-05-15 |
| 2023-09-30 | $58.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $108.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $128.00K 10-Q · filed 2023-05-15 |
| 2022-09-30 | $23.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $40.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $59.00K 10-Q · filed 2022-05-13 |
| 2021-09-30 | $17.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $125.00K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $115.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |